Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple transactions on Form 4. On 03/07/2025 he disposed of 5,700 Class A shares as a gift to a donor-advised fund, leaving 291,439 shares beneficially owned. On 09/24/2025 he exercised 2,100 stock options with an exercise price of $5.01 under a Rule 10b5-1 trading plan adopted 03/04/2025, and concurrently sold 2,100 shares at $56.52. The Form 4 shows 2,100 underlying shares from the options and indicates total Class A beneficial ownership figures of 174,042 shares for options and 291,439–293,539 shares across reported lines. The filing discloses that the options vest over a four-year service schedule that began in 03/2022.
Hims & Hers Health, Inc. (HIMS) Chief Financial Officer Oluyemi Okupe sold 23,584 shares of Class A common stock on 09/22/2025 at an average weighted price of $57.7411 per share under a Rule 10b5-1 trading plan adopted May 21, 2025. Following the sale, the reporting person directly beneficially owns 105,400 shares and indirectly owns 7,853 shares held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021. The filer certifies the sales were effected under the pre-established plan and offers to provide the exact breakdown of shares sold at each price within the reported $57.38–$58.245 range if requested by regulators or the issuer.
Form 144 notice by a holder of HIMS Class A common stock proposes sale of 2,100 shares on 09/24/2025 through Fidelity Brokerage Services (NYSE). The filer indicates the 2,100 shares were acquired the same day as an option exercise tied to an option granted on 02/24/2022 and the consideration is listed as compensation. The filing lists prior sales by the same person, Michael Y. Chi, totaling 60,349 shares sold in the past three months for aggregate gross proceeds of $3,599,076.50. The issuer name, SEC file number and the filer CIK/CCC are not provided in the document text. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
Insider sale notice for HIMS (Form 144) — The filer plans to sell 154,958 common shares through Goldman Sachs & Co. LLC on the NYSE with an aggregate market value of $8,941,076.60, against 217,641,958 shares outstanding. The notice lists the securities were largely acquired as compensation: several restricted stock unit grants dated 09/15/2025 (11,747; 4,110; 5,153; 2,574) and earlier stock option-related acquisitions on 02/24/2022 and 03/01/2023. The filing also discloses multiple sales by Oluyemi Okupe in the prior three months, including a 145,000-share sale on 09/15/2025 generating about $8.03 million. The notice affirms the signer is not aware of undisclosed material adverse information.
Hims & Hers Health, Inc. filed a current report to remind investors how it shares important company information with the public. The company explains that news about its business, products, services and corporate updates may be shared across multiple channels, not just through SEC filings or traditional press releases.
Hims & Hers points investors to several key sources: its main consumer websites at hims.com and forhers.com, its investor relations site at investors.hims.com, and its news site at news.hims.com. The company also highlights social media, including its and CEO Andrew Dudum’s accounts on X and LinkedIn, as places where information that could be considered important may appear. The company notes that this list of channels may change over time.
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock. On 09/17/2025 the reporting person disposed of 2,637 shares at $50.50 per share, leaving beneficial ownership of 166,404 shares following the transaction.
The Form 4 notes the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 08/28/2024. The form is signed by an attorney-in-fact, Kimberly Mather, dated 09/19/2025.
Patrick Harrison Carroll, a director and the company's Chief Medical Officer at Hims & Hers Health, Inc. (HIMS), reported a sale of 10,021 shares of Class A common stock on 09/17/2025 at a price of $50.50 per share. After the transaction he beneficially owned 169,940 shares, reported as direct ownership. The filing states the sales were executed under a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The Form 4 was signed by an attorney-in-fact on 09/19/2025. The filing discloses the insider relationship and the exact transaction details without additional commentary.
Irene Becklund, an officer of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock on 09/17/2025. The Form 4 shows she disposed of 8,410 shares at a price of $50.50 per share under transaction code S(1). After the sale, she beneficially owned 1,418 shares. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted August 7, 2024. The Form 4 was signed by Kimberly Mather as attorney-in-fact for Irene Becklund on 09/19/2025.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported an insider sale. On 09/17/2025 he disposed of 13,749 shares of Class A common stock at $50.50 per share, leaving him with 297,139 shares beneficially owned after the transaction. The Form 4 states the sales were executed under a Rule 10b5-1 trading plan adopted by Mr. Chi on March 4, 2025. The filing is signed by Kimberly Mather as attorney-in-fact for Michael Chi on 09/19/2025. The document contains no additional financial results or commentary.
Andrew Dudum, a director, 10% owner and CEO-related reporting person of Hims & Hers Health, Inc. (HIMS), sold 65,110 shares of Class A common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted August 28, 2024. The sales generated an average weighted price of $50.5745 per share, with individual sale prices ranging from $50.06 to $50.94. After the reported transactions, the reporting person beneficially owned 95,315 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 09/19/2025 and includes an undertaking to provide share-by-share price details upon request.